Introduction {#sec1_1}
============

Renal transplant recipients (RTRs) are highly susceptible to infections due to immunosuppressive therapy. Common risk factors are diabetes mellitus, high age, use of catheters, and extended hospitalisation \[[@B1], [@B2]\]. Infectious complications following renal transplantation (RTX) may worsen graft function and are associated with prolonged hospitalisation and increased medication costs, morbidity, and mortality \[[@B1], [@B3]\]. Urinary tract infection (UTI) is the most common bacterial infection after RTX \[[@B1], [@B2], [@B3], [@B4], [@B5]\]. Urinary isolates from RTRs have revealed a significant increase in antibiotic resistance rates, particularly with *Klebsiella pneumoniae* \[[@B4]\]. The burden of UTIs caused by *K. pneumoniae* that produce extended-spectrum beta-lactamase (ESBL+) after RTX is an emerging problem \[[@B4], [@B5], [@B6]\]. Compatible with the possibility of conversion of intestinal carriage into active UTI, a strong association between gut ESBL+ *K. pneumoniae* colonisation and ESBL+ *K. pneumoniae* UTIs in RTRs has been demonstrated \[[@B5]\].

Faecal microbiota transplantation (FMT) is a highly effective and established treatment for recurrent *Clostridium difficile* infection \[[@B7], [@B8]\]. FMT is being considered for other indications where a disrupted intestinal microbiota may contribute to disease pathogenesis \[[@B7]\], and it is an emerging treatment modality for patients with intestinal carriage of multidrug-resistant (MDR) microorganisms \[[@B9], [@B10], [@B11], [@B12]\]. Antimicrobial resistance is an imminent challenge to global public health, and the problem is increasing. The treatment options for MDR bacterial infections are limited \[[@B13]\].

Case Report {#sec1_2}
===========

A 64-year-old Caucasian man with chronic kidney disease secondary to diabetic nephropathy underwent cadaveric renal allotransplantation in 2017. He received standard antibacterial prophylaxis with perioperative cefuroxime and a 6-month treatment with trimethoprim-sulfamethoxazole. The immunosuppressive treatment consisted of tacrolimus (0.1 mg/kg twice daily), mycophenolate mofetil (750 mg twice daily), prednisolone (tapered from 20 mg once daily), and basiliximab (20 mg) just before RTX and on day 4 after RTX as induction therapy. Due to recurrent infections, immunosuppression was gradually reduced. Prednisolone was stopped before FMT. Mycophenolate mofetil was reduced to 500 mg twice daily 51 days after RTX and further to 250 mg twice daily 81 days after RTX. Tacrolimus was gradually reduced to 1 mg twice daily, corresponding to a trough level of approximately 5 µg/L. A ureteral stent was inserted at RTX and removed 1 month later. The patient never achieved good graft function (Fig. [1](#F1){ref-type="fig"}). Graft biopsies made due to rising levels of serum creatinine showed interstitial fibrosis, tubular atrophy, and increasing numbers of sclerotic glomeruli, but no histological signs of cellular or humoral rejection 2 and 3 months after RTX. Donor-specific antibodies were never detected.

Eighty days after RTX the patient was admitted with urosepsis. ESBL+ *K. pneumoniae* was isolated in blood and urine. During the subsequent 5 months, he was hospitalised seven times because of UTI (Fig. [1](#F1){ref-type="fig"}). Each episode of UTI was associated with a further decline in graft function (Fig. [1](#F1){ref-type="fig"}). At each admission, ESBL+ *K. pneumoniae* only fully susceptible to meropenem and ceftazidime-avibactam was isolated in urinary samples. Antimicrobial susceptibility was interpreted according to the European Committee for Antimicrobial Susceptibility Testing. ESBL+ *K. pneumoniae* bacteraemia occurred during two of the admissions. Blood and urinary isolates showed the same antibiotic susceptibility pattern, and whole-genome sequencing confirmed identical isolates in blood and urine.

Standard empiric therapy with piperacillin-tazobactam was initiated at the first three admissions. Based on urinary and blood culture results, antibiotic treatment was changed to meropenem with a median treatment duration of 12 days (range 4--16). Despite a rapid treatment response, UTI recurrence occurred following withdrawal of the antibiotic treatment, with a median of 7 days (range 4--18) from withdrawal to re-admission (Fig. [1](#F1){ref-type="fig"}).

A positron emission tomography-computed tomography scan performed 6 months after RTX showed no focal uptake pattern or urinary tract foci. It was hypothesised that gastrointestinal colonisation with ESBL+ *K. pneumoniae* was the cause of reinfection. A faecal sample made 7 months after RTX confirmed ESBL+ *K. pneumoniae* carriage.

Eight months after RTX, the patient received FMT in an attempt to decolonise the ESBL+ *K. pneumoniae* from the gut. Prior to FMT, the patient further tested positive for *C. difficile* toxin A and B, and consequently treatment with vancomycin 125 mg orally four times per day was initiated 3 days prior to FMT. After FMT, resolution of diarrhoea was achieved. FMT was administered by a nasojejunal tube 2 weeks after the last course of meropenem. No adverse events related to FMT were observed.

FMT was performed within the local clinical FMT framework in compliance with the Danish Tissue Act \[[@B7]\]. Donor faeces were obtained from a healthy blood donor after approved screening results and an approved medical consultation. The screening of the faeces donor consisted of a questionnaire, blood sampling, and faecal sample analysis. A medical consultation was done to verify the consistency between the approved screening results and the overall state of health. At the laboratory, the donated material was cryopreserved, and thawing procedures were performed before the clinical use of donor faeces.

Six days after FMT, the patient was re-admitted with UTI relapse due to ESBL+ *K. pneumoniae* identical with that formerly isolated from urine and blood and successfully treated with meropenem. Subsequently, no further episodes of UTI occurred (Fig. [1](#F1){ref-type="fig"}). The patient was followed during the first 12 months after FMT, and he was without any symptoms of UTI. No further admissions occurred. ESBL+ *K. pneumoniae* could not be isolated in urinary or faecal samples collected at outpatient follow-up 4 and 8 months after FMT.

Discussion {#sec1_3}
==========

This case report provides proof of concept that intestinal carriage of MDR microorganisms may be eradicated using FMT. In this particular patient, we believe that FMT prevented further episodes of UTI and *C. difficile* infection. Reduction of immunosuppression may have facilitated the clinical effect of FMT.

The rational basis for believing that FMT caused the eradication of ESBL+ *K. pneumoniae* is that colonic carrier status caused the recurrent infections and that colonisation was cleared following FMT. One plausible explanation of the single relapse of UTI shortly after FMT might be that restoration of the disrupted intestinal microbiota takes time. The presented RTR had several factors that contributed to UTI risk, including immunosuppressive treatment, diabetes mellitus, and placement of a urinary catheter. Rectal carriage of ESBL+ *K. pneumoniae* is associated with UTIs in RTRs \[[@B5]\], supporting the assumption that intestinal colonisation with ESBL+ *K. pneumoniae* is a predisposing factor for UTIs in RTRs.

A shift in the faecal microbiota composition towards the donor microbial composition as well as restoration of microbial diversity after FMT has previously been documented \[[@B12]\]. In a recent study, 15 patients carrying ESBL+ *Enterobacteriaceae* were treated with FMT in an attempt to achieve intestinal decolonisation, and 20% of the patients became ESBL-negative after the first FMT procedure. Seven patients underwent a second FMT resulting in a intestinal decolonisation rate of 40%, suggesting that repeated FMT procedures increase treatment effectivity \[[@B12]\]. In the present case, a single FMT procedure was sufficient.

RTRs constitute an immunosuppressed population, and the increase in antibacterial resistance is an alarming trend in this population. The incidence of ESBL+ *Enterobacteriaceae* in solid organ transplant recipients has been documented to increase from 13 to 38 to 45% for the first, second, and third UTI episodes, respectively \[[@B10]\]. The intestine is the primary reservoir for colonisation with MDR *Enterobacteriaceae*. Based on this, there is an urgent clinical need for an approach to achieve intestinal decolonisation, particularly among vulnerable patients, including RTRs.

Eradication of intestinal ESBL+ and carbapenemase-producing *Enterobacteriaceae* carriage using FMT was tested in a recent randomised multicentre clinical trial in immunocompetent patients \[[@B14]\]. Of 64 planned patients, 39 were randomised to a 5-day course of oral antibiotics followed by FMT or no intervention. FMT was successful in 9/22 (41%) versus 5/17 (29%) following no intervention, with an odds ratio of 1.7 (95% confidence interval 0.4--6.4) in favour of FMT. The difference was not statistically significant, and the study was underpowered because only 39 of 64 planned patients were included. Further, immunosuppressed patients may have an increased risk of developing sustained colonisation and thereby suffer from infections.

In RTRs, the present and previously published cases support that FMT is a safe and effective treatment option to eradicate intestinal carriage of MDR microorganisms \[[@B9], [@B11], [@B12]\], with subsequent reduction in antibiotics use and hospital admissions. Overall, antimicrobial exposure is associated with antimicrobial resistance \[[@B13]\]. A reduction in carbapenem use is an important antibiotic stewardship intervention. FMT is a preferable antimicrobial-free treatment option that may effectively reduce broad-spectrum antibiotic use and thereby hospital-acquired MDR infections as well as superinfections such as *C. difficile* infection. The potential benefits of applying FMT in patients such as the one in the present report therefore apply to both the patients in question, to antibiotic stewardship, and to health economics.
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